The FDA urged clinical trial sponsors to report outcomes of registered studies, citing a results-reporting gap across the clinical registry landscape. An FDA review found that results were not reported for 30% of registered clinical studies, prompting reminders to about 2,200 entities including drug and device companies and researchers. The agency’s action signals continued tightening of transparency requirements as regulators and payers seek more complete evidence packages for decision-making. It may also affect how companies resource post-trial analytics and publication timelines. For biotech operators, the near-term operational implication is compliance planning across sponsors, contractors, and trial sites to avoid leaving studies in reporting limbo.